Trials / Unknown
UnknownNCT04566796
Effectiveness of Sugammadex on Muscle Relaxant Reversal in Preterm Neonates
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Alexandria University · Academic / Other
- Sex
- All
- Age
- 28 Days
- Healthy volunteers
- Not accepted
Summary
The primary aim of the work is to compare the efficacy of Sugammadex and neostigmine in reversing rocuronium-induced muscle relaxation to reach complete recovery of neuromuscular block (TOF ratio≥ 0.9) in preterm neonates. The secondary aim is to evaluate the safety of using Sugammadex in preterm neonates and to detect any complications that may occur in this age group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sugammadex | give 2 mg/ kg as muscle reversal drug in premature infants |
| DRUG | Neostigmine | give 0.02 mg/ kg atropine and 0.05 mg/kg neostigmine IV. as muscle reversal drug in premature infants |
Timeline
- Start date
- 2020-08-11
- Primary completion
- 2021-02-01
- Completion
- 2021-02-01
- First posted
- 2020-09-28
- Last updated
- 2020-09-28
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04566796. Inclusion in this directory is not an endorsement.